BRCA1 and ovarian cancer: Ratajska and colleagues [83] screened 109 BRCA1/2 negative high-risk breast and/or ovarian cancer patients from North-Eastern Poland for BARD1 germline mutations and identified three different BARD1 variants suspected to be pathogenic (c.1690C>T, p.Gln564X; c.1315- 2A>G; c.1977A>G).